218 related articles for article (PubMed ID: 16258237)
1. Antibody engineering for the development of therapeutic antibodies.
Kim SJ; Park Y; Hong HJ
Mol Cells; 2005 Aug; 20(1):17-29. PubMed ID: 16258237
[TBL] [Abstract][Full Text] [Related]
2. Tailor-made antibody therapeutics.
Chowdhury PS; Wu H
Methods; 2005 May; 36(1):11-24. PubMed ID: 15848071
[TBL] [Abstract][Full Text] [Related]
3. Generation of antibody molecules through antibody engineering.
Kipriyanov SM
Methods Mol Biol; 2003; 207():3-25. PubMed ID: 12412465
[No Abstract] [Full Text] [Related]
4. Humanization and Simultaneous Optimization of Monoclonal Antibody.
Kuramochi T; Igawa T; Tsunoda H; Hattori K
Methods Mol Biol; 2019; 1904():213-230. PubMed ID: 30539472
[TBL] [Abstract][Full Text] [Related]
5. Antibody therapeutics, antibody engineering, and the merits of protein stability.
Demarest SJ; Glaser SM
Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
[TBL] [Abstract][Full Text] [Related]
6. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.
Beiboer SH; Reurs A; Roovers RC; Arends JW; Whitelegg NR; Rees AR; Hoogenboom HR
J Mol Biol; 2000 Feb; 296(3):833-49. PubMed ID: 10677285
[TBL] [Abstract][Full Text] [Related]
7. Antibody engineering.
Maynard J; Georgiou G
Annu Rev Biomed Eng; 2000; 2():339-76. PubMed ID: 11701516
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic antibodies: magic bullets hit the target.
Gura T
Nature; 2002 Jun; 417(6889):584-6. PubMed ID: 12050630
[No Abstract] [Full Text] [Related]
9. Engineering the variable region of therapeutic IgG antibodies.
Igawa T; Tsunoda H; Kuramochi T; Sampei Z; Ishii S; Hattori K
MAbs; 2011; 3(3):243-52. PubMed ID: 21406966
[TBL] [Abstract][Full Text] [Related]
10. Humanization and simultaneous optimization of monoclonal antibody.
Kuramochi T; Igawa T; Tsunoda H; Hattori K
Methods Mol Biol; 2014; 1060():123-37. PubMed ID: 24037839
[TBL] [Abstract][Full Text] [Related]
11. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology.
Huang C
Curr Opin Biotechnol; 2009 Dec; 20(6):692-9. PubMed ID: 19889530
[TBL] [Abstract][Full Text] [Related]
12. Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats.
Miller A; Carr S; Rabbitts T; Ali H
MAbs; 2020; 12(1):1752529. PubMed ID: 32316838
[TBL] [Abstract][Full Text] [Related]
13. Generation and production of engineered antibodies.
Kipriyanov SM; Le Gall F
Mol Biotechnol; 2004 Jan; 26(1):39-60. PubMed ID: 14734823
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes].
Siberil S; Dutertre CA; Boix C; Teillaud JL
Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389
[TBL] [Abstract][Full Text] [Related]
15. Engineered pH-dependent recycling antibodies enhance elimination of Staphylococcal enterotoxin B superantigen in mice.
Kroetsch A; Qiao C; Heavey M; Guo L; Shah DK; Park S
MAbs; 2019; 11(2):411-421. PubMed ID: 30526311
[TBL] [Abstract][Full Text] [Related]
16. Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1.
Chen W; Bardhi A; Feng Y; Wang Y; Qi Q; Li W; Zhu Z; Dyba MA; Ying T; Jiang S; Goldstein H; Dimitrov DS
MAbs; 2016; 8(4):761-74. PubMed ID: 26963639
[TBL] [Abstract][Full Text] [Related]
17. Recombinant antibodies for cancer diagnosis and therapy.
Hudson PJ; Souriau C
Expert Opin Biol Ther; 2001 Sep; 1(5):845-55. PubMed ID: 11728219
[TBL] [Abstract][Full Text] [Related]
18. Optimization of Fc-mediated effector functions of monoclonal antibodies.
Strohl WR
Curr Opin Biotechnol; 2009 Dec; 20(6):685-91. PubMed ID: 19896358
[TBL] [Abstract][Full Text] [Related]
19. Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs.
Aires da Silva F; Corte-Real S; Goncalves J
BioDrugs; 2008; 22(5):301-14. PubMed ID: 18778112
[TBL] [Abstract][Full Text] [Related]
20. Immunobiological aspects of therapeutic antibodies and related characterization approaches.
Liu PM; Handl H; Zou L; Kim B
Curr Opin Drug Discov Devel; 2007 Sep; 10(5):515-22. PubMed ID: 17786849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
